1416013-62-1

Basic information

• Product Name: 2-Amino-4-bromo-3-fluorobenzoic acid
• Synonyms: 2-Amino-4-bromo-3-fluorobenzoic acid
• CAS NO: 1416013-62-1
• Molecular Formula: C₇H₅BrFNO₂
• Molecular Weight: 234.0225032
• Mol File: 1416013-62-1.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 332.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.877±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 4.37±0.10(Predicted)
• CAS DataBase Reference: 2-Amino-4-bromo-3-fluorobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-4-bromo-3-fluorobenzoic acid(1416013-62-1)
• EPA Substance Registry System: 2-Amino-4-bromo-3-fluorobenzoic acid(1416013-62-1)

Safety Data

• Hazardous Substances Data: 1416013-62-1(Hazardous Substances Data)

Usage

Uses

2-Amino-4-Bromo-3-Fluorobenzoic Acid is used in preparation of Quinazoline compounds as KRAS modulators and antitumor agents.

Synthesis

The synthesis of 2-Amino-4-bromo-3-fluorobenzoic acid is as follows:To a mixture of 6-bromo-7-fluoroindoline-2,3-dione (18.9 g, 77.5 mmol) in 2 N NaOH (350 mL) at 0?oC, H2O2?(30%, 40 mL) was added. The mixture was stirred at room temperature for 16 h. The mixture was quenched with Na2SO3, and the mixture was acidified with conc. HCl to adjust pH to 2. The precipitate was collected by filtration and dried to afford the desired product as a white solid (17 g, 94% yield).

Upstream product

• 58534-95-5 3-bromo-2-fluorobenzenamine 
• 1336963-95-1 6-bromo-7-fluoroindoline-2,3-dione 
• 1416013-61-0 (E)-N-(3-bromo-2-fluorophenyl)-2-(hydroxyimino)acetamide 
• 58534-94-4 2-fluoro-3-bromonitrobenzene 
• 1336963-99-5 N-(3-bromo-2-fluorophenyl)-2-(hydroxyimino)acetamide 

Downstream Products

• 1698027-17-6 2-amino-4-bromo-5-chloro-3-fluorobenzoic acid 
• 1698024-73-5 1-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one 
• 1825390-63-3 methyl 2-amino-4-bromo-3-fluorobenzoate 

Relevant articles and documents

Fused pyridone compounds as kinase inhibitors

The invention discloses a fused pyridone compound serving as a kinase inhibitor, and particularly discloses a compound represented by formula (I). The optical isomer and pharmaceutically acceptable salt thereof as well and as application of the compound as KRAS inhibitor.

CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF

Conjugates of a cereblon-binding compound and compounds having modulatory activity against G12C mutant KRAS, HRAS or NRAS G12C proteins are provided. Methods associated with preparation and use of such conjugates, pharmaceutical compositions comprising such conjugates and methods to modulate the activity of G12C mutant KRAS, HRAS or NRAS G12C proteins for treatment of disorders, such as cancer, are also provided.

INHIBITORS OF KRAS G12C MUTANT PROTEINS

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein A, B R1, R2a, R2b, R3a, R3b, R4a, R4b, G1, G2, m1, m2, L1, L2 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.